Mazdutide

DRUG12 trials

Sponsors

Eli Lilly and Company, Shanghai Zhongshan Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Shandong Provincial Hospital

Conditions

Alcohol Use DisorderCoronary Heart DiseaseDementia, MildDiabetes Mellitus, Type 2Fatty PancreasHepatic SteatosisImpaired Fasting GlucoseImpaired Glucose Tolerance (Prediabetes)

Phase 1

Efficacy of Mazdutide for Treating PCOS

RecruitingNCT06519656

Shanghai Zhongshan HospitalPolycystic Ovary Syndrome

Start: 2024-10-21End: 2026-06-30Target: 50Updated: 2024-10-24

Phase 2

A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

CompletedNCT06124807

Eli Lilly and CompanyObesity, Overweight and Obesity

Start: 2023-11-17End: 2025-07-09Updated: 2026-04-21

A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder

CompletedNCT06817356

Eli Lilly and CompanyAlcohol Use Disorder

Start: 2025-02-06End: 2026-05-19Updated: 2026-07-16

Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)

Not yet recruitingNCT07718126

West China HospitalHepatic Steatosis, Living Liver Donors, Metabolic Dysfunction-Associated Steatohepatitis

Start: 2026-09-01End: 2028-08-31Target: 60Updated: 2026-07-21

Phase 3

Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)

RecruitingNCT07083154

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolDementia, Mild, Mild Cognitive Impairment, Type 2 Diabetes

Start: 2025-09-27End: 2029-08-01Target: 420Updated: 2026-09-02

A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor

Not yet recruitingNCT07417306

Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Type 2 Diabetes

Start: 2026-03-27End: 2027-12-31Target: 912Updated: 2026-02-18

Phase 4

Mazdutide for Adults With Prediabetes: A Randomized, Double-Blind, Placebo-Controlled Trial (DREAM-PRE)

Not yet recruitingNCT07654062

Shandong Provincial HospitalImpaired Fasting Glucose, Impaired Glucose Tolerance (Prediabetes), Prediabetes

Start: 2026-07-01End: 2029-07-01Target: 150Updated: 2026-06-17

Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity

Not yet recruitingNCT07657676

China National Center for Cardiovascular DiseasesCoronary Heart Disease, Obesity & Overweight

Start: 2026-09-01End: 2027-12-31Target: 116Updated: 2026-08-28

QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy

Not yet recruitingNCT07775846

Huijie ZhangType 2 Diabetic Kidney Disease

Start: 2026-09-01End: 2029-06-30Target: 820Updated: 2026-08-20

Unknown Phase

ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management

RecruitingNCT07517042

Shanghai Zhongshan HospitalObesity, Weight Control

Start: 2026-04-01End: 2028-12-01Target: 420Updated: 2026-04-08

Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial

Not yet recruitingNCT07767552

Yanbing LiDiabetes Mellitus, Type 2

Start: 2026-09-30End: 2029-06-30Target: 249Updated: 2026-08-17

Efficacy of Mazdutide on Fatty Pancreas

Not yet recruitingNCT07803705

Tongji HospitalFatty Pancreas, Obesity, Overweight

Start: 2026-11-15End: 2028-12-30Target: 194Updated: 2026-09-04

Related Papers

Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.

2026-08-21

1733-P: Effect of Mazdutide on Kidney Function in Adults with Obesity or Overweight

Diabetes2026-06-05

1693-P: Mazdutide Improves Markers of Insulin Sensitivity in Adults with Obesity without Type 2 Diabetes

Diabetes2026-06-05